EEF2K and esophageal cancer: It is suggested that eEF2K inhibitors can be developed as sensitizing agents to improve the outcomes of radiotherapy, as was shown by the in vivo efficacy in an esophageal cancer xenograft of such treatment in combination with compound 1.